[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 5271 Introduced in Senate (IS)]

<DOC>






118th CONGRESS
  2d Session
                                S. 5271

To require the Administrator of the Drug Enforcement Administration to 
  temporarily exempt buprenorphine from the Suspicious Orders Report 
    System for the remainder of the opioid public health emergency.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                           September 25, 2024

 Mr. Heinrich introduced the following bill; which was read twice and 
               referred to the Committee on the Judiciary

_______________________________________________________________________

                                 A BILL


 
To require the Administrator of the Drug Enforcement Administration to 
  temporarily exempt buprenorphine from the Suspicious Orders Report 
    System for the remainder of the opioid public health emergency.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Broadening Utilization of Proven and 
Effective Treatment for Recovery Act'' or the ``BUPE for Recovery 
Act''.

SEC. 2. REMOVAL OF BUPRENORPHINE PRODUCTS FROM SORS DURING OPIOID 
              PUBLIC HEALTH EMERGENCY.

    (a) Temporary Exemption.--The Administrator of the Drug Enforcement 
Administration shall temporarily exempt any buprenorphine product 
approved for the treatment of opioid use disorder from the Suspicious 
Orders Report System established under 312 of the Controlled Substances 
Act (21 U.S.C. 832), including subsection (a)(3) of that section, until 
that date that is 270 days after the date on which the public health 
emergency with respect to opioids declared by the Secretary of Health 
and Human Services pursuant to section 319 of the Public Health Service 
Act (42 U.S.C. 247d) on October 26, 2017, expires.
    (b) Report.--Not later than 90 days after the date of the 
expiration of the public health emergency described in subsection (a), 
the Department of Justice and the Department of Health and Human 
Services shall--
            (1) conduct a comprehensive report that indicates if the 
        temporary exemption under subsection (a) resulted in increased 
        access to buprenorphine treatment for patients experiencing 
        opioid use disorder; and
            (2) make a recommendation to the White House and Congress 
        about whether buprenorphine should remain in the Suspicious 
        Orders Report System and be subject to related reporting 
        requirements after the expiration of the public health 
        emergency described in subsection (a).
    (c) Sense of Congress.--It is the sense of Congress that Congress 
is concerned by reports of patients not being able to fill 
buprenorphine prescriptions for the treatment of opioid use disorder at 
pharmacies. Reports indicate that pharmacies are unable or unwilling to 
stock sufficient buprenorphine products, in part because of the 
Suspicious Orders Report System and related reporting requirements. A 
temporary exemption of buprenorphine products approved for the 
treatment of opioid use disorder from Suspicious Order Report System 
requirements would allow the Federal Government to collect relevant 
data and assess whether a permanent exemption should be established.
                                 <all>